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Abstract 1 
Background: Knowledge of HIV status (KOS) among people living with HIV (PLHIV) is essential for 2 
an effective national HIV response. This study estimates progress and gaps in reaching the UNAIDS 3 
2020 target of 90% KOS, and the efficiency of HIV testing services (HTS) in sub-Saharan Africa (SSA), 4 
where two thirds of all PLHIV live. 5 
Methods: We used data from 183 population-based surveys (N=2.7 million participants) and national 6 
HTS programs (N=315 country-years) from 40 countries as inputs into a mathematical model to examine 7 
trends in KOS among PLHIV, median time from HIV infection to diagnosis, HIV testing positivity, and 8 
proportion of new diagnoses among all positive tests, adjusting for retesting. 9 
Findings: Across SSA, KOS steadily increased from 6% (95% credible interval [95%CrI]: 5% to 7%) in 10 
2000 to 84% (95%CrI: 82% to 86%) in 2020. Twelve countries and one region, Southern Africa, reached 11 
the 90% target. In 2020, KOS was lower among men (79%) than women (87%) across SSA. PLHIV aged 12 
15-24 years were the least likely to know their status (65%), but the largest gap in terms of absolute 13 
numbers was among men aged 35-49 years, with over 700,000 left undiagnosed. As KOS increased from 14 
2000 to 2020, the median time to diagnosis decreased from 10 to 3 years, HIV testing positivity declined 15 
from 9% to 3%, and the proportion of first-time diagnoses among all positive tests dropped from 89% to 16 
42%. 17 
Interpretation: On the path towards the next UNAIDS target of 95% diagnostic coverage by 2030, and 18 
in a context of declining positivity and yield of first-time diagnoses, we need to focus on addressing 19 
disparities in KOS. Increasing KOS and treatment coverage among older men could be critical to reduce 20 
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 3 
Research in Context 33 
Evidence before this study 34 
One of the major health policy objective of the last decade in the global HIV response has been the 35 
adoption of targets to end the AIDS epidemic by 2030. UNAIDS and its partners put forth in 2014 the 36 
90-90-90 objective to increase HIV diagnosis, treatment, and viral load suppression. They called for 90% 37 
of all people living with HIV to have knowledge of their HIV status (KOS) by 2020. There is clear 38 
evidence of increases in treatment coverage in sub-Saharan Africa (SSA), but little attention has been 39 
devoted to the “first 90” and trends in KOS have not been systematically reviewed and compared.  40 
We searched PubMed from inception to March 2020 without language restriction with the terms 41 
“HIV”[Title/Abstract] AND (“test*”[Title/Abstract] OR “diagnos*”[Title/Abstract] OR 42 
“knowledge”[Title/Abstract]) AND (“Africa”[MeSH] OR “Africa”[Title/Abstract]),  the websites from 43 
the Joint United Nations Programme on HIV/AIDS (UNAIDS), and the World Health Organization for 44 
HIV testing reports and guidelines. Several studies and reports present KOS estimates for selected 45 
countries but none comprehensively examined KOS trends by country, age, and sex, or provided 46 
estimates of HIV testing services (HTS) efficiency. 47 
Added value of this study 48 
Due to incomplete HIV surveillance data, and to non-disclosure of HIV positive status in most 49 
population-based surveys, assessment of KOS is challenging and not uniform in SSA. By triangulating 50 
household survey data about the proportion of adults ever tested for HIV and HTS program data on the 51 
total annual number of HIV tests performed among adults using a mathematical model of testing 52 
behaviors, this study is the first to systematically and comprehensively assess how KOS and HTS 53 
efficiency evolved in SSA over 20 years, and with stratification by sex, age, and region. 54 
Implications of the available evidence 55 
The last two decades witnessed remarkable increases in KOS across SSA, but stark sex, age, and regional 56 
disparities remain, even in countries that have met the 90% target overall. Concomitant decreases in 57 
median time to diagnosis, HIV testing positivity, and proportion of new diagnoses among all positive 58 
tests highlight one of the major challenges faced by testing programs – targeting of HTS to achieve 59 
greatest yield of new diagnoses as the undiagnosed population shrinks and diagnosis delays are reduced. 60 
With national HIV control programs now contemplating how to reach the next UNAIDS target of 95% 61 
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diagnostic coverage by 2030, there is a need to focus on addressing disparities in KOS and to better 62 
understand retesting patterns. 63 
Introduction 64 
Efficient and effective HIV testing services (HTS) are a key component to efforts to end the AIDS 65 
epidemic. A positive diagnosis enables people living with HIV (PLHIV) to receive life-saving 66 
antiretroviral therapy (ART)1 and, for pregnant women living with HIV, risk of mother-to-child HIV 67 
transmission can be almost entirely prevented.2 At the population level, early diagnosis and treatment 68 
could reduce incidence by dramatically lowering viremia such that those with a suppressed viral load are 69 
unable to contribute to onward transmission.3  HTS also helps identify people who are vulnerable to HIV 70 
acquisition and link them to effective HIV prevention services (e.g., voluntary male medical 71 
circumcision, pre-exposure prophylaxis).4 72 
In sub-Saharan Africa (SSA), where more than two-thirds of PLHIV reside,5 HTS were initially provided 73 
through voluntary counselling and testing upon request in stand-alone sites.6 As HIV treatment became 74 
more widely available, provider-initiated HIV testing and counselling emerged, expanding HIV testing 75 
services to all patients in health facilities. HTS was also integrated into antenatal care, which greatly 76 
increased testing coverage among pregnant and postpartum women.6 Such facility-based services were 77 
gradually expanded and implementation of community-based services enabled underserved rural and 78 
marginalized key populations to be reached by HTS and treatment.7-9 The development of new testing 79 
technologies and strategies — including point-of-care rapid diagnostic tests, self-testing, partner testing 80 
and home-based testing — provided opportunities to accelerate delivery of results and linkage to care.10  81 
Recognizing the individual and population benefits of HIV testing and treatment, in 2014, the Joint 82 
United Nations Program for HIV/AIDS (UNAIDS) proposed ambitious targets to strengthen the HIV 83 
treatment and care cascade such that, by 2020, 90% of PLHIV know their status, 90% of those diagnosed 84 
receive ART, and 90% of those treated have a suppressed viral load; with each target increasing to 95% 85 
by 2030.11 These targets are widely adopted globally, and have motivated shifts in the delivery of HTS, 86 
especially in SSA countries with the greatest epidemic burden. Countries monitor and report annually to 87 
UNAIDS their progress towards these targets. 88 
However, the proportion of PLHIV who know their status is particularly challenging to monitor in SSA 89 
because neither the number of PLHIV, nor the number who are diagnosed, are directly counted. Estimates 90 
for PLHIV typically come from mathematical models synthesising HIV serosurvey and antenatal testing 91 
data ¾ for example, the UNAIDS-supported Spectrum model.12 Aggregate HTS data including the 92 
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number of HIV tests conducted and number of HIV diagnoses, are routinely collected, but reports are 93 
often not deduplicated and rates of retesting and re-diagnosis can be high.13,14 Household surveys provide 94 
cross-sectional data about testing history by HIV status at intervals roughly every five years in most 95 
countries, but only a few surveys directly ask respondents if they are aware of their HIV status, a sensitive 96 
question that has high potential for non-disclosure.15-17 These challenges are compounded by imprecise 97 
estimates for the number of new infections by age, sex and geographical area, and by incomplete 98 
ascertainment of mortality among the previously diagnosed and undiagnosed population. 99 
Nearing the UNAIDS’ interim 2020 target deadline, we sought to evaluate progress towards the ‘first 90’ 100 
HIV diagnosis target in SSA, describe the impact of HTS programs on knowledge of HIV positive status 101 
(KOS) and timeliness of HIV diagnosis over the 2000-2020 period, and identify remaining gaps in who 102 
is being reached by HTS. We synthesized data from 40 SSA countries about HIV testing history from 103 
population-based surveys, HTS program data, and HIV epidemic indicators using a validated 104 
mathematical model specifically designed to estimate KOS.13 In addition to trends in KOS and diagnosis 105 
gaps, we estimated time from HIV infection to diagnosis, probability of getting tested within one year of 106 
infection or before reaching a CD4 cell count threshold lower than 350 CD4 cells per µL, positivity 107 
(proportion of HIV-positive tests among all tests), diagnosis yield (proportion of new diagnoses among 108 
all tests), and proportion of new diagnoses among positive tests. 109 
Methods 110 
Overview 111 
We previously developed and validated a compartmental deterministic mathematical model (named 112 
Shiny90), to synthesize multiple data sources into a coherent framework to longitudinally estimate KOS. 113 
This model has been described in detail elsewhere.13 Briefly, Shiny90 models the transition of individuals 114 
aged ≥15 years between six stages: 1) HIV-susceptible who have never been tested, 2) HIV-susceptible 115 
ever tested, 3) PLHIV who have never been tested, 4) PLHIV unaware who have ever been tested, 5) 116 
PLHIV aware (not on ART), and 6) PLHIV on ART. Household surveys and HTS program data are used 117 
to estimate the rates of HIV testing among adults not living with HIV and those living with HIV, where 118 
HIV testing rates vary with calendar time, sex, age, previous HIV testing status, awareness of status, and, 119 
for PLHIV, CD4 cell count category (as a marker of risk of AIDS-related symptoms motivating care-120 
seeking and HIV testing).13 In this way, the proportion of PLHIV who know their status estimated by 121 
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Shiny90 is bound by ART coverage (minimum) and the proportion of PLHIV who have ever been tested 122 
and received the results (maximum). 123 
Data sources and model calibration 124 
Shiny90 uses inputs for HIV incidence, mortality, and ART coverage estimated and reported by national 125 
governments using the UNAIDS-supported Spectrum modeling software and its Estimation and 126 
Projection Package.12 The Spectrum model calculates epidemic statistics stratified by age, sex, CD4 cell 127 
count category, and ART status. Parameter estimates for HIV disease progression and mortality, as well 128 
as demographic rates, are also informed by Spectrum.  129 
Two main data sources are used for estimation of HIV testing rates during model calibration: 130 
1) The proportion of individuals (³15 years old) who self-report having ever been tested for 131 
HIV and received the result of the last HIV test from national household surveys conducted 132 
between 2000-2019. Estimates were stratified by sex, age (15-24, 25-34, and 35-49 years old), and, 133 
if available, HIV sero-status. Sources of national household surveys included Demographic and 134 
Health Surveys (DHS; https://dhsprogram.com/Data/), AIDS Indicator Surveys (AIS), Multiple 135 
Indicator Cluster Surveys (MICS; www.mics.unicef.org/surveys), Population-based HIV Impact 136 
Assessments (PHIA; https://phia-data.icap.columbia.edu/files), and other country-specific surveys 137 
(Figure 1). The model was calibrated to data on the proportion ever tested for HIV, but we did not 138 
calibrate to self-reported awareness of status data, due to evidence of non-disclosure.15-17 139 
2) Data on the total annual number of HIV tests performed among individuals aged ≥15 years 140 
and, where available, total number of positive HIV tests (2000-2019) reported by national HIV 141 
testing programs. HTS program data are particularly informative about changes in testing levels 142 
after the most recent available population-based survey.13 143 
For the analyses reported here, we used the Shiny90 country files submitted to UNAIDS in 2020 144 
(www.unaids.org/en/dataanalysis/datatools/spectrum-epp), including Spectrum, surveys, and program 145 
data. Additional programme data sources are listed in appendix (pp 47-50). 146 
Sub-saharan African countries with at least one available survey stratified by HIV sero-status, or 147 
countries with surveys not stratified by HIV sero-status but having at least one HTS program data set 148 
including total number of positive tests between 2000-2019 were included in analyses. These were the 149 
minimal set of survey and HTS program data that were required to calibrate the model for a given 150 
country. Countries with a population under 250,000 people, or without available survey data, or with 151 
 . CC-BY 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted October 23, 2020. ; https://doi.org/10.1101/2020.10.20.20216283doi: medRxiv preprint 
 7 
only survey data not stratified by HIV sero-status and no HTS program data between 2000-2019 were 152 
excluded from analyses. 153 
For each country, the model estimates rates of HIV testing by sex, age, HIV status, and testing and 154 
treatment history were estimated from the household survey and HTS program data in a Bayesian 155 
framework. The mode of the posterior distribution was estimated via optimisation with the Broyden-156 
Fletcher-Goldfarb-Shanno algorithm18 and the posterior density was approximated via Laplace 157 
approximation around the posterior mode.13 Conceptually, the HTS program data inform rates of HIV 158 
testing in the population, while changes in the proportion ever tested by HIV status, sex, and age, 159 
alongside estimates of HIV incidence and mortality, inform the proportion of tests conducted among 160 
those being HIV tested or diagnosed for the first time versus repeat testing.13  161 
Estimating knowledge of HIV status, positivity, and yield 162 
Using Shiny90 we calculated annual (2000-2020) proportions of PLHIV with KOS (% of all PLHIV who 163 
have ever tested HIV-positive and are thus aware of their HIV status), positivity (% of all HIV tests that 164 
are positive), yield of new diagnoses (% of new diagnoses out of all HIV tests), and the proportion of 165 
new diagnoses out of all positive tests. For post-2019 model predictions, rates of HIV testing were 166 
assumed to remain constant at their 2019 values, but with amplified uncertainty guided by variation in 167 
historical testing rates. These projections were also guided by historical increases in ART coverage, with 168 
coverage achieved in 2020 extrapolated from the 2016-2019 rates of ART initiation. No adjustments 169 
were made for the possible impact of coronavirus disease 2019 (COVID-19) disruptions. All indicators 170 
can be stratified by sex and age group, and aggregated to regional level by weighting each country’s 171 
indicator by the number of estimated PLHIV from Spectrum for that calendar year. 172 
Estimating time to diagnosis 173 
From the annual sex- , age- , HIV testing history- , and CD4 cell count-specific testing rates, we 174 
calculated several cross-sectional indicators using period life table methods19 that account for the 175 
competing risk of AIDS-related death. These include: time from HIV infection to diagnosis, probability 176 
of getting tested within one year following infection and before reaching a CD4 count threshold lower 177 
than 350 cells per µL. These indicators were calculated annually by constructing individual period life 178 
tables for each of the 16 baseline strata of sex (men, women), age groups (15-24, 25-34, 35-49, and 50+ 179 
years), and HIV testing history (never tested, ever tested). Because the estimates are from period life 180 
tables, they reflect the distribution of time to diagnosis if a person who seroconverted in a given year was 181 
to experience that year’s HIV testing rates by age and CD4 category for their remaining lifetime. Details 182 
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of the calculations are presented as supplementary materials (appendix p 1). For each calendar year 183 
between 2000 and 2020, we estimated these indicators for the 16 age/sex/testing history strata separately. 184 
They were then aggregated to the desired demographic or geographic level (e.g., age, sex, country, region 185 
[Western, Central, Eastern, and Southern Africa]) by weighting each stratum by the estimated number of 186 
new HIV infections in that stratum for that year (obtained from Spectrum). 187 
Uncertainty 188 
We obtained uncertainty intervals by drawing 1,000 samples from the posterior distribution of the testing 189 
rates estimated by Shiny90. We summarized all indicators using the median, 2.5th and 97.5th percentile 190 
of their posterior distribution. We performed analyses using R version 3.5.1 and the Rcpp packages.20 191 
The code for Shiny90 is available on a public repository (www.github.com/mrc-ide/first90release). We 192 
followed the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER, appendix 193 
p 51).21 194 
Ethical approval 195 
All analyses were performed on anonymized and deidentified data. All DHS/AIS survey protocols have 196 
been approved by the Internal Review Board of ICF International in Calverton (USA) and by the relevant 197 
country authorities for other surveys (MICS and PHIA). Further information on the ethics approval can 198 
be found in the individual country reports. Ethics approval for secondary data analyses was obtained 199 
from McGill University’s Faculty of Medicine Institutional Review Board (A10-E72-17B). 200 
Role of the Funding Source 201 
The funders of the study played no role in study design, data collection, data analysis, data interpretation, 202 
or writing of the report. The corresponding author had full access to all the data in the study and had final 203 
responsibility for the decision to submit for publication. 204 
Results 205 
A total of 40 countries, 183 population-based surveys (>2.7 millions surveyed individuals), and 315 206 
country-years of HTS program data reports informed our model (Figure 1). Four SSA countries (Cabo 207 
Verde, Central African Republic, Guinea-Bissau, Mauritius) were excluded from the analyses due to 208 
insufficient data inputs for model calibration, and one (Sao Tome and Principe), because of high 209 
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uncertainty in epidemic statistics for small population sizes (<250,000 people). Results of the Shiny90 210 
model calibration are presented in Text S2 (appendix pp 2-42). 211 
Across SSA, the proportion of adults 15 years and older (both those living and not living with HIV) 212 
estimated to have been tested increased by 48 percentage points from 2000 to 2020 (Table 1). Testing 213 
coverage was highest in Southern Africa with 85% (95%CrI: 83 to 88%) of adults projected to have ever 214 
been tested in the region in 2020. 215 
The proportion of adult PLHIV with KOS increased steadily from 5.7% (95%CrI: 4.6 to 7.0%) in 2000 216 
to 84% (95%CrI: 82 to 86%) in 2020 in SSA (Table 1). While KOS increased dramatically in all four 217 
SSA regions, KOS was consistently lower in Western and Central Africa as compared to Eastern and 218 
Southern Africa (Figure 2A; Figure S1: appendix p 43). Within the regions, national estimates were also 219 
highly heterogeneous, especially in Eastern Africa with a 77 percentage point difference between the 220 
countries with the lowest and highest KOS estimates. Overall, we projected that 12 countries (Figure 3) 221 
and one region, Southern Africa, will have reached at least 90% KOS in 2020. Countries with higher 222 
KOS tended to be those in which the annual number of tests relative to the total population aged ≥15 223 
years was highest (Figure S2: appendix p 44). 224 
Our results also suggest disparities in KOS by sex and age. Across SSA in 2020, men had lower KOS 225 
(79%, 95%CrI: 76 to 81%) than women (87%, 95%CrI: 85 to 89%), and 15-24 year-olds were the least 226 
likely to know their status (65%, 95%CrI: 62 to 69%; Figure 2B-C, Table S4: appendix p 53). Such 227 
disparities were also observed among the 12 countries projected to achieve at least 90% of KOS overall 228 
in 2020. Of these countries, only six are projected to achieve 90% of KOS among men, and none are 229 
projected to do so among the 15-24 year-olds. 230 
While the proportion of PLHIV aware of their status was lower among younger adults, the absolute 231 
number of PLHIV was also lower. Consequently, in absolute numbers, the largest group of undiagnosed 232 
PLHIV in SSA were men aged 35-49 years, with >700,000 left undiagnosed and 305,000 diagnoses 233 
needed to reach 90% awareness of status (Figure 4, Table S3: appendix p 52). 234 
The median time from HIV infection to diagnosis (or death) decreased by 7 years from 2000 to 2020 for 235 
all of SSA (Table 1; Figure 5A). That is, if projected HIV testing rates in 2020 persisted into the future, 236 
50% of people infected in 2020 would be diagnosed (or, with small probability, suffer AIDS-related 237 
mortality) within 2.6 years of seroconverting. National trends are presented in Figure S3 (appendix p 45). 238 
Consistent with the estimated decreases in median time to diagnosis, the probability of receiving an HIV 239 
test within 1 year following infection or before reaching a CD4 count threshold lower than 350 cells per 240 
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µL increased respectively by 31 and 52 percentage points from 2000 to  2020 in SSA (Table 1; Figure 241 
5B-C). 242 
The proportion of all HIV tests that are positive (positivity) decreased by 6 percentage points from 2000 243 
to  2020 (Table 1; Figure S4: appendix p 46), and the proportion of new diagnoses among all tests 244 
(diagnosis yield) decreased by 7 percentage points. Concommitantly, the proportion of new diagnoses 245 
among positive tests decreased by 47 percentage points over the study period (Table 1). That is, we 246 
project that 58% of PLHIV undergoing testing in 2020 will have been previously diagnosed with HIV. 247 
For each of the previous outcomes, five-yearly estimates are presented by sex and age stratification and 248 
by region in Tables S4 to S8 (appendix pp 53-57). 249 
Discussion 250 
Across SSA, impressive gains were achieved in KOS with 84% (95%CrI: 82 to 86%) of PLHIV being 251 
aware of their HIV positive status, and 12 countries and the region of Southern Africa that are projected 252 
to reach the 90% KOS target in 2020. Concomitant with these improvements, we estimated that median 253 
time from HIV acquisition to diagnosis would be reduced to 2.6 years (95%CrI: 1.8 to 3.5) over that 254 
period. 255 
Despite this progress, our results highlight substantial regional, national, sex, and age disparities in KOS 256 
in SSA. KOS was consistently lower in Western and Central Africa than Eastern and Southern Africa. 257 
In those regions, HIV prevalence is lower but key populations — including sex workers, men who have 258 
sex with men, and people who inject drugs — account for a higher HIV burden. For example, they 259 
generally represent a small fraction of the population but accounted for 42% of all new HIV infections 260 
in 2019 in the region of Western and Central Africa.5 Stigma and discrimination towards key populations 261 
are common in many health facilities, which may lead to delayed HIV testing, concealment of HIV 262 
positive status, and/or poor uptake of HIV services.22 A recent systematic review and meta-analysis has 263 
shown that, among men who have sex with men in Africa, lower testing and KOS were associated with 264 
more hostile legislation, and that KOS remained low in the region.23 To improve coverage of HIV health 265 
services in Western and Central Africa, antidiscrimination and protective laws to eliminate stigma and 266 
discrimination among key populations should be implemented and enforced, health workers trained and 267 
sensitized, and key population-friendly services provided.22 Eastern Africa, despite having high KOS 268 
across the region, includes the two countries with the lowest KOS—South Sudan and Madagascar. While 269 
new HIV infections  declined overall in Eastern African countries between 2010 and 2019, new infections 270 
in South Sudan and Madagascar are estimated to have increased by 17% and 191%, respectively.5 This 271 
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underscores that reducing new HIV infections, ‘turning off the tap’ of undiagnosed PLHIV, is key to 272 
reaching KOS targets. 273 
In all four SSA regions, and consistent with previous studies, men are less likely to know their HIV status 274 
compared to women.24-28 Overall, the diagnosis gap is such that there is a 8% point difference between 275 
men and women in 2020. Large differences in KOS are also observed between age groups, with the 276 
lowest proportion diagnosed being among PLHIV aged 15-24 years. Importantly, all countries have yet 277 
to reach 90% KOS in this younger group. This gap between age groups is the natural consequence of 278 
HIV transmission dynamics. HIV incidence is highest and average time since infection is short — and 279 
thus cumulative exposure to testing is lower — in this age group compared to older ones.12 To achieve 280 
90% KOS among 15-24 years-old would require a simultaneous increase in testing with greater 281 
investment in HIV prevention to increase coverage of high impact prevention interventions.  282 
While we found that KOS was proportionally the lowest among men aged 15-24 years old, the largest 283 
group of undiagnosed PLHIV was men aged 35-49 years, with >700,000 projected to be undiagnosed in 284 
2020. Lower uptake of HIV testing among men may be explained by fewer opportunities for testing as 285 
well as other social and system-wide barriers such as harmful gender norms7,29 and inaccessible or 286 
unfriendly services.30 Engaging men in HIV prevention efforts is critically important, not only for their 287 
own needs, but also for their sexual partners. An increase in KOS and of treatment coverage among older 288 
men could be critical to reduce HIV acquisition rates among women, and by extension, reducing mother-289 
to-child transmission. Among different testing approaches, community-based testing, door-to-door HTS, 290 
home-based couples testing, workplace programs, mobile testing services, social network interventions, 291 
incentives to test, self-testing, and partner notification have shown success in increasing diagnostic 292 
coverage among men.31 As part of these efforts, facilitating linkage and retaining men with HIV care 293 
remains a key challenge for further progress towards HIV testing and treatment targets.  294 
Despite improvements, especially in Southern Africa where the median time to diagnosis (or AIDS-295 
death) was estimated at 1.5 years (95%CrI: 0.9 to 2.3) in 2020, we projected that across SSA and at 296 
current testing levels, 50% of PLHIV will not be diagnosed within 3 years following their infection, and 297 
29% will not get tested before reaching a CD4 count threshold lower than 350 cells per µL in 2020. These 298 
diagnostic delays impede rapid ART initiation at high CD4 counts which, in its absence, contribute to 299 
increased HIV morbidity and onward HIV transmission.1,32-34 Reducing diagnostic delays on their own 300 
will likely not be enough to improve individual and population health outcomes. Earlier diagnosis should 301 
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be accompanied by rapid ART linkage and long-term adherence to ART ¾ these are crucial to 302 
minimizing morbidity and reducing HIV incidence.32,33,35 303 
As the undiagnosed population shrinks and diagnosis delays are reduced, targeting of HTS to achieve 304 
greatest yield of new diagnoses is one of the major challenges faced by testing programs.36 Although we 305 
noted an ecological correlation between a country’s testing volume with respect to its population of 306 
reproductive age and KOS, we also estimated a decline in positivity and in the yield of new diagnoses. 307 
Such declining yields are an inevitable consequence of reaching saturation in testing programs ¾ as long 308 
as testing rates are lower in previously-diagnosed individuals than in undiagnosed, we can expect yields 309 
to decline as KOS increases. Our analyses also highlight substantial retesting of PLHIV already aware 310 
of their status. We projected that 58% of positive tests will be performed on previously diagnosed PLHIV 311 
in SSA in 2020. In previous studies conducted in SSA between 2004 and 2018, retesting among PLHIV 312 
with known HIV status was also common, ranging from 13% to 68%.14,37-41 Retesting can be motivated 313 
by multiple factors, one of them being the ability to confirm the accuracy of the initial test result.41-43 314 
Another important driver of retesting may be avoiding disclosing prior knowledge of HIV positive status 315 
due to societal stigma or denial. A recent study conducted among persons undergoing HIV testing at a 316 
health facility in South Africa found that 50% of patients testing HIV-positive had previously been in 317 
HIV care (and hence previously diagnosed). Among these, half did not disclose prior knowledge of HIV 318 
status to their health care provider.14 Further research is needed to assess the potential benefits of retesting 319 
for reengaging PLHIV in care. 320 
This analysis has some limitations. First, Shiny90 does not provide estimates of diagnosis coverage 321 
among <15 years-old, nor can it disaggregate metrics by key population groups. Second, we could have 322 
overestimated KOS in some low HIV prevalence countries where key populations are disproportionately 323 
affected by HIV if these groups are underrepresented in population-based surveys. Third, uncertainty in 324 
the PLHIV denominator, HIV incidence estimates, and ART coverage are not accounted for. This does 325 
not affect the validity of point estimates, but their precision could be overestimated. Fourth, we assumed 326 
that HIV testing does not result in false negative or false positive results. The assumption of no false 327 
negative HIV test result may have slightly over-estimated KOS and probability of getting tested within 328 
1 year or before reaching a CD4 count threshold lower than 350 cells per µL, and under-estimated median 329 
time to diagnosis or (AIDS-related death). The number of HIV diagnoses reported in HTS programme 330 
data could be inflated if WHO-recommended retesting to verify HIV diagnosis before ART initiation 331 
was incorrectly counted as separate HIV diagnoses, which our model would not be able to identify from 332 
routinely reported data. Fifth, we also assumed that self-reporting of HIV testing histories was accurate 333 
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but social desirability and recall biases could result in underestimation of the proportion ever tested and, 334 
ultimately, of KOS.44 However, validation of self-reported HIV testing histories by mean of antiretroviral 335 
biomarkers data from PHIA surveys from eSwatini, Malawi, Tanzania, and Zambia using Bayesian latent 336 
class model suggest that, self-reported HIV testing history being highly sensitive, underestimation of the 337 
proportion ever tested and of KOS should be low (Xia et al. preprint).45 Sixth, earlier estimates of 338 
diagnosis delays are informed by relatively few population-based survey estimates and HTS program 339 
data. Given the cross-sectional nature of these metrics, they could be more sensitive to the elicited 340 
model's prior distributions in early years. Finally, the impact of measures taken to prevent the spread of 341 
COVID-19 in some countries could have affected both HIV incidence and HTS.46 Such unacounted 342 
factors could potentially lead to slightly lower KOS estimates than those projected in 2020, although a 343 
notable decrease would be unlikely since already diagnosed PLHIV would remain so. 344 
Although previous studies examined HIV testing uptake or self-reported KOS at community or country 345 
level, the present analysis is believed to be the first to systematically and comprehensively assess how 346 
HTS efficiency evolved in SSA over 20 years. By using a unified framework to compare HTS metrics, 347 
consistency and comparability of results between the different outcomes, countries, and regions is 348 
improved. A second strength is the large number of surveys and program data used for triangulation, 349 
improving the precision and robustness of our results. Third, in assessing time to diagnosis (or AIDS-350 
related death) and other related metrics, we provide valuable information to help programs optimize HTS 351 
efficiency.47 With clear individual and population-health benefits of early treatment initiation, reducing 352 
diagnostic delays and improving linkage to care will contribute towards the ultimate goal to end AIDS 353 
epidemics by 2030. 354 
Conclusion 355 
In 2014, the world adopted the goal of achieving 90% HIV diagnosis by 2020. Sub-Saharan Africa, the 356 
most affected region, is close to reaching this target and we project that 12 countries and one region, 357 
Southern Africa, will have reached that goal among adults in 2020. However, reaching 90% diagnosis 358 
coverage remains challenging and our results shed light on stark sex and age gaps in KOS. None of the 359 
12 countries projected to reach the 90% target overall are projected to do so in all age and sex groups. 360 
National HIV control programs are now contemplating how to reach the next UNAIDS target of 95% 361 
diagnostic coverage by 2030 in a context of declining positivity, declining yields of “true” new diagnoses, 362 
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and COVID-19 disruption. Reaching this objective will require a better understanding of retesting 363 
patterns and a focus on addressing disparities among older men and young people in KOS. 364 
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Figure 1: Summary of included surveys and HIV testing services program data by country and year, 2000-2019 
Circles represent surveys that were conducted among both men and women, while squares and triangles represent surveys 
that were conducted among women or among men only, respectively. White dots indicate surveys where results on the 
proportion of individuals who self-report having ever been tested for HIV are not available by HIV status. Horizontal lines 
represent HIV testing services program data. DHS: Demographic Health Survey. AIS: AIDS Indicator Survey; MICS: 
Multiple Indicator Cluster Survey; PHIA: Population-based HIV Impact Assessment Survey. Other types of surveys include: 
Population Health Survey from Eritrea, South African National HIV Prevalence, Incidence, Behaviour and Communication 
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Figure 2: Progress and disparities in knowledge of HIV status in sub-Saharan Africa, 2000-2020 
Panels A to C show trends in proportion of people living with HIV (PLHIV) who are aware of their HIV status in sub-Saharan 
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Figure 3: National estimates of knowledge of HIV status in sub-Saharan Africa, 2020 
Proportion of PLHIV who know their HIV status. The horizontal yellow line represents a threshold of 90% and vertical lines 
correspond to the 95% credible intervals. 
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Figure 4: Absolute diagnosis gaps in sub-Saharan Africa, 2020 
Each bar shows the total number of undiagnosed people living with HIV (PLHIV) by sex- and age-stratification. Vertical 
lines correspond to the 95% credible intervals. 
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Figure 5: Progress in timeliness of HIV diagnosis in sub-Saharan Africa, 2000-2020 
Regional trends in median time to diagnosis or AIDS-related death (A), in the probability to get tested within one year (B) 
or before reaching a CD4 count threshold lower than 350 cells per µL (C) were assessed through period life-table analyses. 
The shaded areas correspond to the 95% credible intervals. 
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Table 1: Regional progress in HIV testing related outcomes among adults 15 years and older in sub-Saharan Africa, 
2000-2020 
Outcome Year Sub-Saharan Africa Western Africa Central Africa Eastern Africa Southern Africa 
Proportion of 
individuals (³15 years 
old) ever tested for 
HIV among overall 
population (%) 
2000 3·6 (3·0 to 4·4) 3·1 (2·6 to 3·8) 1·9 (1·3 to 2·6) 3·3 (2·8 to 3·9) 10 (8·3 to 13) 
2005 11 (10 to 12) 7·2 (6·6 to 7·8) 7·8 (6·6 to 9·2) 13 (12 to 14) 30 (29 to 32) 
2010 30 (29 to 32) 19 (18 to 19) 19 (17 to 22) 41 (39 to 42) 59 (58 to 61) 
2015 41 (40 to 42) 28 (27 to 29) 29 (28 to 30) 53 (52 to 54) 75 (74 to 75) 
2020 51 (49 to 54) 36 (34 to 39) 42 (39 to 48) 64 (62 to 66) 85 (83 to 88) 
Proportion of PLHIV 
who know their HIV 
status (%) 
2000 5·7 (4·6 to 7·0) 4·0 (2·8 to 5·2) 3·2 (2·0 to 4·6) 4·8 (4·0 to 5·8) 9·3 (7·5 to 12) 
2005 20 (18 to 22) 10 (7·7 to 12) 15 (12 to 18) 19 (17 to 21) 27 (25 to 30) 
2010 53 (50 to 55) 33 (28 to 35) 37 (32 to 41) 56 (53 to 58) 60 (58 to 63) 
2015 71 (69 to 73) 52 (48 to 55) 53 (47 to 56) 74 (72 to 75) 79 (77 to 80) 
2020 84 (82 to 86) 67 (65 to 69) 70 (64 to 76) 86 (85 to 88) 90 (88 to 92) 
Time to diagnosis or 
AIDS-related death, 
median (year) 
2000 9·6 (9·1 to 10) 11 (10 to 11) 11 (10 to 12) 11 (10 to 11) 7·7 (7·0 to 8·4) 
2005 7·2 (6·3 to 8·0) 10 (9·4 to 11) 8·2 (7·1 to 9·3) 7·3 (6·3 to 8·2) 5·9 (5·1 to 6·6) 
2010 3·6 (3·2 to 4·1) 5·5 (4·9 to 6·5) 6·1 (5·2 to 7·3) 3·2 (2·8 to 3·6) 2·8 (2·5 to 3·1) 
2015 3·0 (2·7 to 3·4) 5·2 (4·5 to 6·0) 4·7 (3·9 to 6·0) 2·6 (2·4 to 2·9) 2·2 (1·9 to 2·4) 
2020 2·6 (1·8 to 3·5) 5·4 (4·1 to 6·5) 3·9 (2·2 to 6·0) 2·0 (1·5 to 2·7) 1·5 (0·9 to 2·3) 
Probability of getting 
tested within 1 year 
following infection 
(%) 
2000 2·6 (2·1 to 3·3) 1·6 (1·1 to 2·1) 1·5 (1·0 to 2·1) 1·7 (1·4 to 2·1) 4·2 (3·3 to 5·3) 
2005 5·9 (4·5 to 7·7) 1·8 (1·1 to 2·6) 5·1 (3·6 to 7·1) 5·8 (4·4 to 7·6) 7·5 (5·8 to 9·7) 
2010 21 (18 to 25) 11 (7·7 to 14) 9·3 (6·5 to 13) 25 (21 to 29) 23 (20 to 26) 
2015 26 (23 to 30) 13 (9·3 to 17) 12 (7·8 to 18) 31 (28 to 35) 28 (25 to 32) 
2020 33 (23 to 46) 12 (7·0 to 19) 16 (7·6 to 34) 40 (29 to 52) 40 (26 to 60) 
Probability of getting 
tested before reaching 
a CD4 count lower 
than 350 cells/µL (%) 
2000 19 (16 to 23) 13 (9·3 to 16) 12 (8·3 to 17) 14 (11 to 16) 30 (25 to 35) 
2005 35 (29 to 42) 14 (9·2 to 19) 30 (22 to 38) 35 (29 to 42) 43 (37 to 50) 
2010 63 (58 to 66) 45 (36 to 51) 43 (34 to 51) 66 (62 to 70) 69 (66 to 72) 
2015 67 (63 to 70) 47 (38 to 53) 52 (41 to 60) 71 (68 to 74) 75 (72 to 77) 
2020 71 (62 to 79) 44 (32 to 56) 59 (39 to 75) 77 (70 to 83) 81 (72 to 89) 
Positivity (% of 
positive tests among 
all tests) 
 
2000 9·0 (7·7 to 10) 3·0 (2·1 to 3·5) 4·6 (3·5 to 5·2) 11 (9·6 to 12) 15 (13 to 19) 
2005 11 (9·2 to 14) 4·0 (3·3 to 4·5) 5·4 (4·2 to 6·7) 10 (9·1 to 12) 20 (16 to 26) 
2010 5·9 (4·3 to 8·3) 2·6 (2·0 to 3·2) 5·0 (3·6 to 6·9) 5·6 (4·2 to 7·5) 13 (9·0 to 22) 
2015 4·3 (3·5 to 5·2) 2·2 (1·7 to 2·7) 3·4 (2·4 to 4·7) 4·0 (3·5 to 4·6) 9·2 (7·1 to 13) 
2020 2·8 (2·1 to 3·9) 1·9 (1·3 to 2·7) 2·2 (1·4 to 3·3) 2·5 (1·9 to 3·3) 5·5 (3·8 to 8·4) 
Diagnosis yield (% of 
new diagnoses among 
all tests) 
2000 7·9 (7·0 to 8·6) 2·6 (1·8 to 2·9) 4·2 (3·2 to 4·7) 9·7 (8·8 to 11) 13 (12 to 14) 
2005 7·8 (7·0 to 8·4) 3·2 (2·7 to 3·6) 3·8 (3·1 to 4·3) 7·6 (7·0 to 8·1) 14 (12 to 15) 
2010 2·8 (2·4 to 3·3) 1·5 (1·2 to 1·7) 2·6 (2·1 to 3·0) 2·4 (2·1 to 2·9) 6·9 (6·2 to 7·5) 
2015 1·9 (1·7 to 2·1) 1·1 (0·9 to 1·3) 1·6 (1·2 to 1·8) 1·7 (1·6 to 1·8) 4·4 (4·1 to 4·6) 
2020 1·2 (0·9 to 1·5) 1·0 (0·7 to 1·5) 0·9 (0·6 to 1·3) 1·0 (0·8 to 1·3) 2·2 (1·6 to 2·9) 
Proportion of new 
HIV diagnoses among 
all positive tests (%) 
 
2000 89 (77 to 96) 86 (79 to 94) 93 (85 to 97) 91 (85 to 95) 87 (70 to 97) 
2005 72 (55 to 86) 79 (71 to 90) 71 (55 to 86) 74 (61 to 84) 70 (48 to 87) 
2010 48 (33 to 65) 56 (46 to 73) 52 (36 to 71) 44 (32 to 59) 53 (31 to 76) 
2015 44 (37 to 53) 48 (38 to 61) 46 (33 to 59) 42 (37 to 48) 47 (34 to 60) 
2020 42 (30 to 55) 52 (38 to 68) 42 (24 to 57) 41 (30 to 52) 39 (25 to 55) 
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